Related Experiment Video
Updated: Jul 19, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group
A E O'Donnell1, A F Barker, J S Ilowite
1Division of Pulmonary Medicine, Georgetown University Medical Center, Washington, DC, USA.
Study Objective:
To study the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis.
Design:
Double-blind, randomized, placebo-controlled, multicenter study.
Populations:
Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland.
Interventions And Measurements:
Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period.
Results:
Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial.
Conclusions:
rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.
More Related Videos
Related Concept Videos
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
COPD: Management Using Bronchodilators and Corticosteroids
Pulmonary Cycle: Exhalation
Rheumatic Heart Disease III: Medical Management
Respiratory Syncytial Virus Disease

